ADA and myeloid sarcoma: Therefore both ADA isoenzymes may serve as therapeutic targets for MS with the potential to decrease the adhesion mode exhibited by ADA1, inhibit their catalytic activity, or induce the growth factor properties of ADA2 by, for example, the recently proposed pegylated-ADA2 (PEG-ADA2) treatment (Wang et al., 2021).